|
Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of ...
Sacramento Bee Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases. For more information, please visit http://www.insmed.com. ... |
Read the full story:
Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of ... - Sacramento Bee
You must log in to post a comment.